Dipeptidyl peptidase-4 inhibitors

PreclinicalSmall molecule

Dipeptidyl peptidase-4 inhibitors is one of 94 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Type 2 DiabetesActive, not recruiting

Urinary Tract InfectionActive, not recruiting

Type 2 Diabetes MellitusPreclinical

Active, not recruiting

Type 2 DiabetesPreclinical

Active, not recruiting

Urinary Tract InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

55 2

Jardiance

Boehringer Ingelheim

Preclinical

31 3

Glargine

Eli Lilly

Preclinical

8 4

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 5

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 6

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 7

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 8

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 9

Forxiga

AstraZeneca

Preclinical

3 10

Acipimox

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT03751657·247 enrolled

Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT04017221·1,249,636 enrolled

Advanced1 trial

Feasibility of DPP-4 Inhibitor Therapy on Advanced Hybrid Closed Loop System

Completed·—·Phase 3·NCT06021119·50 enrolled

Urinary Tract Infection1 trial

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03764631·1,502 enrolled

Cardiovascular Events1 trial

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT03939624·419,734 enrolled

Type 2 Diabetes Mellitus1 trial

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03492580·714,582 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Dipeptidyl peptidase-4 inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dipeptidyl peptidase-4 inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dipeptidyl peptidase-4 inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

Dipeptidyl peptidase-4 inhibitors

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes2 trials

Advanced1 trial

Urinary Tract Infection1 trial

Cardiovascular Events1 trial

Type 2 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News